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OBJECTIVES: Although early recognition of sepsis is vital to improv-
ing outcomes, the diagnosis may be missed or delayed in many patients. 
Acute kidney injury is one of the most common organ failures in patients 
with sepsis but may not be apparent on presentation. Novel biomarkers for 
acute kidney injury might improve organ failure recognition and facilitate 
earlier sepsis care.
DESIGN: Retrospective, international, Sapphire study.
SETTING: Academic Medical Center.
PATIENTS: Adults admitted to the ICU without evidence of acute kidney 
injury at time of enrollment.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We stratified patients 
enrolled in the Sapphire study into three groups—those with a clinical di-
agnosis of sepsis (n = 216), those with infection without sepsis (n = 120), 
and those without infection (n = 387) at enrollment. We then examined 
30-day mortality stratified by acute kidney injury within each group. Finally, 
we determined the operating characteristics for kidney stress markers (tis-
sue inhibitor of metalloproteinases-2) × (insulin-like growth factor binding 
protein 7) for prediction of acute kidney injury as a sepsis-defining organ 
failure in patients with infection without a clinical diagnosis of sepsis at en-
rollment. Combining all groups, 30-day mortality was 23% for patients who 
developed stage 2–3 acute kidney injury within the first 3 days compared 
with 14% without stage 2–3 acute kidney injury. However, this difference 
was greatest in the infection without sepsis group (34% vs 11%; odds 
ratio, 4.09; 95% CI, 1.53–11.12; p = 0.005). Using a (tissue inhibitor of 
metalloproteinases-2) × (insulin-like growth factor binding protein 7) cutoff 
of 2.0 units, 14 patients (11.7%), in the infection/no sepsis group, tested 
positive of which 10 (71.4%) developed stage 2–3 acute kidney injury. 
The positive test result occurred a median of 19 hours (interquartile range, 
0.8–34.0 hr) before acute kidney injury manifested by serum creatinine or 
urine output. Similar results were obtained using a cutoff of 1.0 for any 
stage of acute kidney injury.
CONCLUSIONS: Use of the urinary (tissue inhibitor of metalloprotein-
ases-2) × (insulin-like growth factor binding protein 7) test could identify 
acute kidney injury in patients with infection, possibly helping to detect 
sepsis, nearly a day before acute kidney injury is apparent by clinical criteria.
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Early recognition of sepsis is a key to improv-ing outcomes. Timely antibiotics and source control, recognition and reversal of shock, and 
provision of organ support are cornerstones of sepsis 
management. These actions are different from those 
taken in patients with infection without sepsis. For this 
reason, sepsis care protocols have been developed to 
capture these cornerstones of treatment and are imple-
mented at many, if not most, hospitals.
A pragmatic definition of sepsis has been devel-
oped in which infection-associated organ dysfunction 
is the central tenant (1). Implicit in this definition is 
the notion that clinicians can identify organ dysfunc-
tion as well as its relationship to infection. The three 
most common organ dysfunctions in sepsis are car-
diovascular (i.e., shock), renal (i.e., acute kidney in-
jury [AKI]), and respiratory, each occurring in 50% 
or more of patients (2). For previously healthy adults, 
shock and hypoxemia are usually easy to recognize, 
and other organ failures such as mental status changes 
can produce obvious and dramatic symptoms as well. 
However, early detection of AKI can be difficult since 
it does not cause symptoms and changes in serum cre-
atinine, and urine output can be delayed relative to 
organ damage. In some patients, occult (normoten-
sive) shock may occur, but arterial lactate levels can be 
used to identify these patients. Similarly, oxygen satu-
rations or arterial blood gases can help detect respira-
tory failure. Importantly, even in patients with septic 
shock, AKI is associated with a substantial increased 
risk of death—27.7% for stage 2–3 AKI versus 6.2% for 
patients without AKI (3).
Biomarkers to detect AKI prior to clinical/lab-
oratory indicators of kidney dysfunction are now 
routinely available. The NephroCheck Test (Astute 
Medical, San Diego, CA) measures the product of 
two biomarkers, tissue inhibitor of metalloproteinases 
(TIMP)–2 and insulin-like growth factor binding pro-
tein (IGFBP) 7. At a cutoff of 2.0 (ng/mL)2/1,000, the 
test has a specificity of 95% to predict Kidney disease 
improving global outcomes (KDIGO) stage 2–3 AKI 
in the next 12 hours (4). We have previously shown 
that the test performs well in patients with sepsis with 
an area under the receiver operating characteristics 
curve of 0.84 (5). Thus, urinary (TIMP-2) × (IGFBP7) 
might serve as a means to identify occult sepsis (i.e., 




We conducted our analysis using a previously published 
cohort of critically ill patients (Sapphire) in which uri-
nary (TIMP-2) × (IGFBP7) was measured and complete 
details are reported elsewhere (6). Briefly, Sapphire in-
cluded 728 adult subjects with critical illness defined as 
cardiac or respiratory failure and without evidence of 
AKI at enrollment. After excluding five patients enrolled 
under consent from a legally authorized representative 
who later died prior to reconsent, we analyzed 723 sub-
jects. The primary endpoint was moderate-to-severe 
AKI (KDIGO stage 2–3) within 12 hours of sample 
collection. Data were collected by the investigators and 
analyzed by independent statisticians not directly affil-
iated with the study. The study protocol was approved 
by the Western Institutional Review Board (Olympia, 
WA) and also by the institutional review board or 
ethics committee of each study site, as required. All 
patients (or authorized representatives) provided writ-
ten informed consent. We defined infection and sepsis 
based on the clinical diagnosis assigned by the treating 
physicians at enrolling sites at the time of enrollment. 
Antibiotics were prescribed for 98% of patients with 
infection without sepsis. AKI was defined and staged 
using full KDIGO criteria (both serum creatinine and 
urine output) (7) based on interpolation (linear) across 
each hour to provide precise timing for AKI manifesta-
tion. The design, execution, and reporting of this study 
meet the Strengthening the Reporting of Observational 
Studies in Epidemiology (8) and the Standards for 
Reporting of Diagnostic Accuracy criteria (9).
Measurements
Paired urine and serum samples for biomarker and cre-
atinine assessment, respectively, were obtained at the 
time of enrollment and within 24 hours of ICU admis-
sion, flash-frozen, stored at less than or equal to –70°C, 
and thawed immediately prior to analysis. TIMP-2 
and IGFBP7 concentrations were measured by immu-
noassay with the NephroCheck Test on the Astute140 
Meter (Astute Medical, San Diego, CA) by technicians 
blinded to clinical data. The TIMP-2 and IGFBP7 con-
centrations in ng/mL were multiplied and divided by 
1,000 to obtain the composite (TIMP-2) × (IGFBP7) 
results in units of (ng/mL)2/1,000. We assessed 
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severity of illness and organ dysfunction/failure with 
the Acute Physiology and Chronic Health Evaluation 
(APACHE)–III (10) and Sequential Organ Failure 
Assessment (SOFA) (11) scores. Nonrenal APACHE-
III and SOFA scores were calculated by subtracting the 
renal components from these scores.
Statistics
We stratified patients into three groups—those with 
a clinical diagnosis of sepsis (n = 216), those with in-
fection without a clinical diagnosis of sepsis (n = 120), 
and those without infection (n = 387) at enrollment. 
All patients had either respiratory or cardiac dysfunc-
tion or both; thus, in the infection without sepsis group, 
organ failure was not attributed to infection. AKI status 
was determined within the first 3 days after enrollment, 
and mortality was assessed for up to 9 months from 
enrollment. We compared 30-day mortality rates be-
tween patients with or without AKI for each infection 
group by using a logistic regression model. Rates are 
expressed as proportions, and time to event is reported 
as median with interquartile ranges (IQRs) among 
patients with events. Mortality out to 9 months was 
plotted using Kaplan-Meier curves stratified by both 
urinary (TIMP-2) × (IGFBP7) and AKI. Differences 
between strata were analyzed using the log-rank test. 
Hazard ratios for 9-month mortality by urinary (TIMP-
2) × (IGFBP7) and AKI strata were determined using 
Cox proportional hazards analysis. For comparisons 
of baseline characteristics across the three infection 
groups or between pairs of groups, categorical variables 
were analyzed using Fisher exact test and continuous 
variables using Kruskal-Wallis test across three groups 
and Wilcoxon rank-sum test for pairwise comparisons. 
A p value of less than 0.05 was considered to indicate 
statistical significance. All reported p values are two 
sided. All analyses were performed using R 3.4.4 (R 
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Baseline Characteristics
Of the 723 patients enrolled in Sapphire, 216 had a 
clinical diagnosis of sepsis at enrollment, whereas 120 
had infection as a primary or secondary diagnosis but 
without a clinical diagnosis of sepsis. The remainder 
(n = 387) had neither infection nor sepsis at enrollment. 
Baseline characteristics for the cohort as a whole, as 
well as broken out by these three categories, can be 
found in Table 1 (with additional analysis provided 
in Supplemental Table 1, http://links.lww.com/CCM/
G112). Compared with patients with a diagnosis of 
sepsis at enrollment, those with infection only had 
lower severity of illness by APACHE and SOFA but 
were otherwise comparable.
AKI Rates and Outcomes
Across the entire cohort, 175 patients (24.2%) devel-
oped stage 2–3 AKI within the first 3 days after enroll-
ment. Mortality at 30 days was 23% for patients who 
developed stage 2–3 AKI compared with 14% without 
stage 2–3 AKI (p = 0.003). Comparison of AKI rates 
and outcomes across the three groups are shown in 
Table 2. Patients with infection with or without sepsis 
had similar rates of stage 2–3 AKI (27.3% vs 26.7%) 
and 30-day mortality (20.4% vs 17.5%). However, 
patients with infection without a diagnosis of sepsis 
had a larger differential effect on mortality from stage 
2–3 AKI (34% vs 11%; odds ratio [OR] 4.09; 95% CI, 
1.53–11.12; p = 0.005) compared with (27% vs 18%; 
OR, 1.71; 95% CI, 0.84–3.44; p = 0.13) for patients with 
sepsis and (17% vs 12%; OR, 1.44; 95% CI, 0.72–2.75; 
p = 0.29) for patients without infection (Fig. 1).
Biomarker Results
Using a urinary (TIMP-2) × (IGFBP7) cutoff of 2.0, 
14 patients (11.7%) in the infection/no sepsis group 
tested positive, of which 10 (71.4%) developed stage 
2–3 AKI. The positive test result occurred a median of 
19 hours (IQR, 0.8–34.0 hr) before stage 2–3 AKI man-
ifested by serum creatinine or urine output. However, 
this timing is based on retrospective interpolation of 
creatinine and urine output values such that the actual 
time for clinical diagnosis was likely much later. To 
explore this further, we excluded three patients who 
would have already met clinical criteria for stage 2–3 
AKI at the time of enrollment based on these extrapo-
lated values. For the remaining patients, the median 
lead time was actually 31 hours (IQR, 19–40 hr). 
We also repeated this analysis using a 1.0 cutoff for 
urinary (TIMP-2) × (IGFBP7) to detect any stage of 
AKI (not just stage 2–3). We found that 24 patients 
(20%) tested positive, of which 18 (75%) developed 
AKI (six were stage 1).
Online Clinical Investigations
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TABLE 1. 
Baseline Characteristics
Characteristics All Patients No Infection
Infection  
No Sepsis Sepsis pa
n 723 387 120 216  
Male, n (%) 444 (61.4) 256 (66.1) 74 (61.7) 114 (52.8) 0.005
Age, median (interquartile range) 64 (53–73) 64 (53–72) 61 (52–73) 66 (54–74) 0.207
Race, n (%)     0.006
 White 568 (78.6) 312 (80.6) 92 (76.7) 164 (75.9)  
 Black 87 (12) 50 (12.9) 18 (15) 19 (8.8)  
 Other/unknown 68 (9.4) 25 (6.5) 10 (8.3) 33 (15.3)  
Medical history, n (%)      
 Chronic kidney disease 65 (9) 41 (10.6) 9 (7.5) 15 (6.9) 0.288
 Diabetes 210 (29) 116 (30) 29 (24.2) 65 (30.1) 0.445
 Congestive heart failure 121 (17.3) 77 (20.6) 12 (10.3) 32 (15.3) 0.023
 Coronary artery disease 215 (30.3) 146 (38.6) 24 (20.2) 45 (21.2) < 0.001
 Hypertension 429 (59.3) 239 (61.8) 56 (46.7) 134 (62) 0.009
 Chronic obstructive  
pulmonary disease
146 (20.2) 81 (20.9) 27 (22.5) 38 (17.6) 0.482
 Cancer 187 (26.2) 88 (23) 30 (25.4) 69 (32.2) 0.050
Reason for ICU admission, n (%)      
 Cardiovascular 239 (33.1) 154 (39.8) 33 (27.5) 52 (24.1) < 0.001
 Cerebrovascular 70 (9.7) 46 (11.9) 13 (10.8) 11 (5.1) 0.017
 Sepsis 135 (18.7) 0 (0) 0 (0) 135 (62.5) < 0.001
 Respiratory 308 (42.6) 116 (30) 73 (60.8) 119 (55.1) < 0.001
 Trauma 55 (7.6) 49 (12.7) 4 (3.3) 2 (0.9) < 0.001
 Surgery 247 (34.2) 180 (46.5) 18 (15) 49 (22.7) < 0.001
 Other 126 (17.4) 47 (12.1) 33 (27.5) 46 (21.3) < 0.001
Enrollment serum creatinine (mg/dL),  
median (interquartile range)
0.8 (0.7–1.1) 0.9 (0.7–1.1) 0.8 (0.6–1.1) 0.8 (0.6–1.1) 0.147
Nonrenal APACHE-III,  
median (interquartile range)
60 (43–82) 57 (41–80) 59 (42–73) 63 (48–87) 0.008
APACHE-III,  
median (interquartile range)
69 (51–91) 67 (50–90) 66 (51–82) 75 (55–96) 0.006
Nonrenal SOFA,  
median (interquartile range)
7 (5–10) 7 (5–10) 7 (4–9.25) 8 (5.75–10) 0.035
SOFA, median (interquartile range) 8 (5–10) 8 (5–10) 7 (4.75–10) 8 (6–11) 0.033
APACHE = Acute Physiology and Chronic Health Evaluation, SOFA = Sequential Organ Failure Assessment.
a Comparisons were made across the three subgroups.
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Long-Term Survival by Biomarkers  
and AKI Status
Finally, we examined mortality out to 9 months strat-
ified by both urinary (TIMP-2) × (IGFBP7) and AKI. 
Figure 2A shows results for the 2.0 cutoff and stage 
2–3 AKI, and Figure 2B shows the 1.0 cutoff and stage 
1–3 AKI. Higher mortality was seen for patients with 
biomarker-positive AKI compared with biomarker-
negative AKI in both analyses. The hazard ratio (95% 
CI) for 9-month mortality was 2.32 (1.46–3.67) for 
patients with stage 2–3 AKI and (TIMP-2) × (IGFBP7) 
greater than 2 relative to patients with no or stage 1 
AKI and (TIMP-2) × (IGFBP7) less than or equal 
to 2. Similarly, the hazard ratio (95% CI) was 2.44 
(1.68–3.54) for patients with any AKI and (TIMP-2) 
× (IGFBP7) greater than 1 relative to patients with no-
AKI and (TIMP-2) × (IGFBP7) less than or equal to 1 
(ng/mL)2/1,000.
DISCUSSION
Despite no specific therapy, sepsis mortality rates have 
steadily decreased in recent years (12). Presumably, this 
is due to better recognition and prompt therapy with 
antibiotics and reversal of shock. Delay of appropriate 
therapy, even by a few hours, can dramatically increase 
mortality (13). As such many hospitals have instituted 
sepsis protocols that are designed to deliver broader 
spectrum antibiotics quickly, screen for shock (lactate), 
and admit to the ICU for close monitoring for organ 
dysfunction. The current definition of sepsis, Sepsis-3, 
is pragmatic requiring infection with related organ 
failure (1). AKI is one of the most common organ fail-
ures and yet can be difficult to identify early. These dif-
ficulties stem from both delayed clinical manifestations 
(serum creatinine and urine output changes) as well 
as from challenges to recognition (e.g., lack of baseline 
creatinine, incomplete urine output data). Importantly, 
AKI is strongly associated with sepsis mortality. In the 
Protocolized Care for Early Septic Shock (ProCESS) 
trial (14), hospital mortality truncated at 60 days was 
6.2% for patients without AKI, whereas it was 16.8% 
for patients with maximum AKI stage 1, and 27.7% 
for stage 2–3 AKI (p = 0.0001) (3). We observed sim-
ilar results here in that 30-day mortality was 27% in 
patients with sepsis and stage 2–3 AKI. Surprisingly, 
in patients with infection and no clinical diagnosis 
of sepsis, 30-day mortality was 34% for patients with 
stage 2–3 AKI compared with 11% without stage 
2–3 AKI. Of course, these patients likely “had” sepsis 
(infection plus AKI) even if it could not be identified at 
enrollment.
Many authors have lamented the difficulty asso-
ciated with screening for sepsis among hospitalized 
patients. Pooled results for 23 studies including more 
than 150,000 non-ICU patients illustrate that quick 
SOFA has poor sensitivity for sepsis mortality (51%) 
and organ failure (47%) (15). Numerous studies have 
shown that urinary (TIMP-2) × (IGFBP7) is sensitive 
and specific for AKI including for patients with sepsis 
(5, 16–18). Many patients with infection are admitted 
to hospital, and, in the absence of shock or respira-
tory failure, few are admitted to ICU. However, AKI 












n 723 387 120 216  
Any AKI within 3 d 413 (57.1) 218 (56.3) 67 (55.8) 128 (59.3) 0.742
Stage 2–3 AKI within 3 d 175 (24.2) 84 (21.7) 32 (26.7) 59 (27.3) 0.229
Renal replacement therapy within 30 d 48 (6.6) 20 (5.2) 8 (6.7) 20 (9.3) 0.158
Death within 30 d 116 (16) 51 (13.2) 21 (17.5) 44 (20.4) 0.060
Major adverse kidney events at 30 d 155 (21.4) 68 (17.6) 27 (22.5) 60 (27.8) 0.014
AKI = acute kidney injury. 
a Comparisons were made across the three subgroups.
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Murugan et al (19) found that AKI occurred in a third 
of patients admitted to hospital with community-
acquired pneumonia (only 16% to the ICU), and yet, 
mortality at 1 year was three-fold higher in patients 
with stage 2–3 AKI. Our patients in this study were all 
admitted to ICU, and yet, an additional 8% of patients 
with infection could be diagnosed with sepsis without 
waiting for AKI to manifest by changes in urine output 
or serum creatinine. These patients could therefore 
have been treated for sepsis much earlier, potentially 
improving outcome. These treatments could have 
included broader spectrum, faster initiation of IV anti-
biotics, greater emphasis on source control (e.g., more 
diagnostic imaging), more use of functional hemody-
namic monitoring, etc.
The downside to this approach is that for every 
four positive tests, one would be a false positive. These 
patients would receive more expensive care, including 
more ICU admissions and more invasive monitoring. 
They might also receive antibiotics generally reserved 
for patients with sepsis. These measures would increase 
costs and risks for these patients, even if only slightly. 
However, these risks need to be balanced against miss-
ing sepsis in nearly one of 10 cases.
Importantly, we can envision clinical implementa-
tion of these findings in a number of settings. First, 
sepsis can be challenging to diagnose in the presence 
of organ failures that appear to be due to the primary 
disease or condition (e.g., shock in a patient following 
cardiac surgery or hypoxia in a patient with an exac-
erbation of chronic lung disease). Thus, patients with 
infection who are in the ICU for another reason are 
at particularly high risk for sepsis, and screening for 
AKI might be very useful. Patients like this are rep-
resented in our study. Second, patients being admit-
ted to the hospital outside the ICU are not as closely 
monitored. Kidney function in particular is not well 
tracked outside the ICU where Foley catheters are 
actively discouraged, and serum creatinine is rarely 
measured more than once daily. In these patients, 
measures of AKI biomarkers might also be helpful. 
However, we did not include these types of patients in 
our study, and because the risk for AKI will be lower, 
false-positive rates will increase. Thus, we recommend 
further study in patients outside the ICU or similar 
high-risk groups. A third category of patients might 
be those being evaluated in the emergency depart-
ment with infection and under consideration for ad-
mission. Diagnosing organ failure in this population 
would significantly alter the care plan. However, this 
group might include very low-risk patients, and thus 
care needs to be taken to select patients for testing. 
A recent study in patients not restricted to infection 
(20) used three criteria to assess high risk for AKI: 
1) critical illness, 2) two or more systemic inflamma-
tory response syndrome criteria (21), or 3) triaged for 
immediate or highly urgent treatment based on the 
manchester triage system (22). Using these criteria, 
the event rate for stage 2–3 AKI among patients with 
Figure 1. Thirty-day mortality by acute kidney injury (AKI) status. 
A, Shows mortality for stage 2–3 AKI versus no-AKI, and stage 
1 stratified by no infection, infection only, and sepsis. B, Shows 
mortality for stage 1–3 AKI versus no-AKI stratified by the same 
three patient groups. *p < 0.05.
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urinary (TIMP-2) × (IGFBP7) greater than 
0.3 was more than 30%.
Finally, across our entire cohort, we found 
important differences in 9-month survival 
when patients with AKI tested positive with 
urinary (TIMP-2) × (IGFBP7) compared 
with when AKI occurred without a positive 
biomarker. Both patients with stage 1 with 
(TIMP-2) × (IGFBP7) greater than 1 and 
stage 2–3 with (TIMP-2) × (IGFBP7) greater 
than 2.0 exhibited worse survival compared 
with biomarker-negative AKI at each re-
spective stage. These results are consistent 
with those reported recently by Joannidis 
et al (23) in which biomarker-positive stage 
1 AKI behaved like stage 2–3 AKI in terms 
of outcomes such as death, dialysis, and per-
sistent stage 3.
The primary study was not designed to 
test the hypotheses we sought to address 
with this secondary analysis. As such, there 
are important limitations. For example, 
patients in the “infection only” group may 
have developed AKI for reasons other than 
sepsis—such as from a nephrotoxic drug. 
Although this is possible, it seems unlikely 
given the strong association with mortality. 
Second, we do not know when or if patients 
in the infection group were diagnosed with 
sepsis, only that it was not recorded in the 
medical record at the time of enrollment. 
The clinical team may have made the diag-
nosis based on other criteria, or they may 
never have diagnosed it. Similarly, we did 
not collect detailed information on the care 
these patients received such as the use of 
functional hemodynamic monitoring, so 
we cannot comment on whether care would 
have changed if the diagnosis of sepsis was 
made sooner. Nevertheless, we can say that 
for these patients, the biomarker correctly 
identified AKI several hours before it could 
be diagnosed using standard criteria.
In conclusion, urinary (TIMP-2) × (IGFBP7) 
could identify AKI as a sepsis-defining organ 
failure in patients with infection several hours 
before clinical diagnosis with less than 30% of 
positive test results being false positives.
Figure 2. Mortality curves out to 9 mo stratified by the both urinary tissue 
inhibitor of metalloproteinases-2 (TIMP-2) × insulin-like growth factor binding 
protein 7 (IGFBP7) and acute kidney injury (AKI). A, Shows results for the 2.0 
cutoff and stage 2–3 AKI. Using no-AKI or stage 1 and (TIMP-2) × (IGFBP7) 
less than or equal to 2 as reference, the individual hazard ratios (95% CI) for 
each group were as follows: 1.27 (0.64–2.49), p = 0.49 for no-AKI/stage 1 and 
(TIMP-2) × (IGFBP7) greater than 2; 1.61 (1.16–2.24), p = 0.005 for stage 2–3 
AKI and (TIMP-2) × (IGFBP7) less than or equal to 2; and 2.32 (1.46–3.67),  
p < 0.001 stage 2–3 AKI and (TIMP-2) × (IGFBP7) greater than 2 (ng/mL)2/ 
1,000. B, Shows the 1.0 cutoff and stage 1–3 AKI. Using no-AKI and (TIMP-
2) × (IGFBP7) less than or equal to 1 as reference, the individual hazard ratios 
(95% CI) for each group were as follows: 0.56 (0.20–1.54), p = 0.26 for no-AKI 
and (TIMP-2) × (IGFBP7) greater than 1; 1.55 (1.12–2.14), p = 0.008 for AKI 
and (TIMP-2) × (IGFBP7) less than or equal to 1; and 2.44 (1.68–3.54),  
p < 0.001 for AKI and (TIMP-2) × (IGFBP7) greater than 1 (ng/mL)2/1,000.
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